DAMORA THERAPEUTICS INC (DMRA)
Health Care · Monoclonal antibodies and immuno-oncology · NASDAQ
Damora Therapeutics is a biotechnology company developing a pipeline of precision antibody therapies specifically targeting mutCALR-driven myeloproliferative neoplasms.
What DAMORA THERAPEUTICS INC does
Damora Therapeutics is a biopharmaceutical company developing therapies for hematologic disorders, specifically targeting myeloproliferative neoplasms (MPNs). The company was created through an acquisition of Pre-Acquisition Damora in November 2025 and obtained a portfolio of three preclinical antibody product candidates (DMR-001, DMR-002, and DMR-003) designed to target mutant calreticulin (mutCALR) through a licensing option agreement with Paragon Therapeutics. The candidates employ distinct antibody mechanisms—including an Fc-null antibody and an afucosylated antibody—with potential to address the full spectrum of mutCALR-driven MPNs.
Themes: hematology / oncology, antibody therapeutics, myeloproliferative neoplasms (MPNs), precision medicine
Fundamentals
- Price$30.82 as of 2026-08-21 close
- Market cap$1.9B as of 2026-08-21
- 1-year return+811.8% 2025-08-21 close $3.38 → 2026-08-21 close $30.82
- P/En/a earnings data not available
- ROE-123.1% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta-4.81 as of 2026-08-24
- Last reported earnings2026-03-10 SEC EDGAR Form 8-K (Item 2.02)
How DMRA compares in its sector
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
DMRA is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no growth data.
Short-term score
62.9 #110 of 1,704 scored · #33 of 241 in Health Care
Trend 81st: it is trading 17.7% above its 50-day average, the short-term trend line; volume and participation 69th: trading volume is about normal versus its 30-day average; weakest is catalysts 36th: open-market insider buys in 90 days 1, analysts' average price target is unchanged from the prior reading.
Scores as of 20 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2. DMRA was not in the scored universe at the latest run on 21 Aug 2026, so these scores are its last ones.
How DAMORA THERAPEUTICS INC looks technically
DAMORA THERAPEUTICS INC (DMRA) is trading 21.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 217 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative). It made a new 20-day high about 24 trading days ago. It is 19.6% below its highest point of the past year. Trading volume is unusually light — only about 39% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 21.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +21.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $27.94 | $27.94 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $25.30 | $25.30 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 31.77. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 217 trading days ago — a "golden cross", a bullish long-term signal | 217 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend) | 18.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30) | 54.0 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($28.48 to $33.56) — its "stochastic" reading is 46 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 46.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $38.33 | $38.33 |
|---|---|---|
| From the 52-week high | it is 19.6% below its 52-week high (its highest price of the past year) | -19.6% |
| Above the 52-week low | it is 1158.0% above its 52-week low (its lowest price of the past year) | +1,158% |
| Below the 52-week high | it is 19.6% below its highest point of the past year | 19.6% |
| Since a 20-day breakout | it made a new 20-day high about 24 trading days ago | 24 sessions |
| Since a 55-day breakout | it made a new 55-day high about 24 trading days ago | 24 sessions |
| All-time high | its highest closing price on record is $449.75 (set on 2020-11-23) | $449.75 |
| Given back of the 52-week move | over the past year its closes ranged ($2.58 to $34.14), and it has given back only a small part of its rise from last year’s low — 11% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $13.63 to $14.64. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 10.5% |
| From the all-time high | it is 93.1% below its all-time high | -93.2% |
| Nearest price level | it is trading 3.3% below a resistance level at $31.82 — a price it turned at three times since 2025-10-07, most recently on 2026-08-05. Since 2024-08-21 it has 6 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +3.3% |
| All-time low | its lowest closing price on record is $2.01 (set on 2025-04-09) | $2.01 |
| Above the all-time low | it is 1433.3% above its all-time low | +1,433% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 86% of it) | 14th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.92 between its high and its low — about 6.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.92 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $28.12 and $32.25 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $28.12 – $30.19 – $32.25 |
| Typical daily range (% of price) | its price moves about 6.2% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.2% |
| Stretch from the 200-day average | it is trading 2.9 daily ranges above its 200-day average price (21.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.9 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 39% of its 30-day average | 0.39× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 2 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 2 sessions ago |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.5% |
|---|---|---|
| Open gap | it gapped 2.5% above the previous close 16 sessions ago and has not traded back through the level it left behind at 28.33 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.5% |
| Gap filled | a 2.4% gap up opened on 2026-08-03 has been "filled" 14 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 14 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 8.9 percentage points (the stock lost 6.6% while the market gained 2.3%) | -8.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 20.9 percentage points (the stock gained 24.0% while the market gained 3.1%) | +20.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 8.3 percentage points (the stock gained 2.7% while the market gained 11.1%) | -8.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 791.4 percentage points (the stock gained 811.8% while the market gained 20.5%) | +791.4% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 14% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-15 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 6.3% of the share price. | +13.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 18% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $26.18 — a volume-weighted average of daily closes over 159 sessions, not a true tick-by-tick VWAP. | +17.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% below the average price paid since it last reported on 2026-08-10 (its 10-Q), so the typical buyer over that stretch is under water. That average is $31.14 — a volume-weighted average of daily closes over 10 sessions, not a true tick-by-tick VWAP. | -1.0% |
Price levels it has turned at before
DMRA last closed at $30.82 on 2026-08-21. Since 2024-08-21 it has turned at 6 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $31.82 | Resistance | 3.3% above the last close | turned there three times · 2025-10-07 to 2026-08-05 |
| $28.47 | Support | 7.6% below the last close | turned there four times · 2026-02-03 to 2026-07-29 |
| $33.45 | Resistance | 8.6% above the last close | turned there twice · 2025-11-11 to 2025-12-17 |
| $26.39 | Support | 14.4% below the last close | turned there twice · 2026-05-27 to 2026-07-13 |
| $23.06 | Support | 25.2% below the last close | turned there twice · 2026-04-07 to 2026-04-29 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $31.77.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) · lagging the market · Most volatile (6%+ typical daily range) · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.10 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$44.67 range $40.00 – $51.00; median $45.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for DMRA
- Consensus EPS estimate-$0.37 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Preclinical-stage portfolio with no human-administered products or approvals; all candidates remain in research phase with uncertain development timelines and no guarantee of clinical or regulatory success","Substantial dependence on DMR-001 and reliance on Paragon Therapeutics for research execution and IP licensing; loss of or inability to maintain these collaborations would materially harm the business","Significant capital requirements to fund future development and commercialization; inability to raise necessary funding on acceptable terms could force reduction or elimination of research programs"]
What changed in the latest 10-Q
AI-assisted comparison of DMRA's 10-Q filed 2026-05-12 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Company name changed to Damora Therapeutics, Inc. (filed 2026-05-12)
- Acquisition of Pre-Merger Damora on November 10, 2025 described with detailed merger structure (filed 2026-05-12)
- Paragon Option Agreement dated October 7, 2025 for licensing intellectual property rights (filed 2026-05-12)
- DMR-001 exclusive license exercise on December 8, 2025 for mutCALR targeting product candidate (filed 2026-05-12)
- DMR-002 exclusive license exercise on April 28, 2026 for second mutCALR targeting product candidate (filed 2026-05-12)
- Option to license DMR-003, a mutCALR and CD-3-targeting product candidate (filed 2026-05-12)
- Research plan engagement with Paragon for DMR-001, DMR-002, and DMR-003 with joint development committee (filed 2026-05-12)
- Company description as developing therapies for hematologic disorders, specifically MPNs (filed 2026-05-12)
- Portfolio of mutCALR targeted therapies with three distinct antibody mechanisms (filed 2026-05-12)
- DMR-001 described as Fc-null antibody designed to block mutCALR-mediated oncogenic signaling (filed 2026-05-12)
- DMR-002 described as afucosylated antibody for antibody-dependent cellular cytotoxicity (filed 2026-05-12)
- DMR-003 described as bi-specific T-cell engager antibody for T-cell-mediated killing (filed 2026-05-12)
- Development of candidates for ET and MF treatment with specific prevalence statistics (25% ET, 35% MF caused by mutCALR) (filed 2026-05-12)
- Planned regulatory submissions timeline: mid-2026 for DMR-001, second half 2026 for DMR-002, 2027 for DMR-003 (filed 2026-05-12)
- Reference to 10-K filed March 19, 2026 for year ended December 31, 2025 (filed 2026-05-12)
- Removed:
- Clinical-stage biotechnology company description (filed 2025-11-06)
- Small molecule therapeutics focus targeting cancer and liver diseases (filed 2025-11-06)
- September 2023 corporate restructuring and workforce reduction (filed 2025-11-06)
- October 7, 2024 strategic alternatives announcement and focus on oncology/severe liver diseases (filed 2025-11-06)
- Bridge Medicines BRM-1420 acquisition and GB3226 program (filed 2025-11-06)
- GB1211 program (filed 2025-11-06)
- GB2064 LOXL-2 inhibitor candidate (filed 2025-11-06)
- Cash sufficiency estimates for preclinical development into 2026 with IND submission (filed 2025-11-06)
- Capital requirements and funding risk disclosure (filed 2025-11-06)
- GB3226 dual inhibitor of ENL-YEATS and FLT3 for AML development (filed 2025-11-06)
- Rockefeller University license agreement for GB3226 (filed 2025-11-06)
- September 2025 FDA pre-IND feedback for GB3226 (filed 2025-11-06)
- First quarter 2026 IND application plan for GB3226 (filed 2025-11-06)
- Phase 1 trial design details for GB3226 in relapsed or refractory AML (filed 2025-11-06)
- 2027 timeline for initial clinical data from GB3226 Phase 1 trial (filed 2025-11-06)
- Background on AML target indication and molecular subsets (filed 2025-11-06)
- AML statistics and market projections (filed 2025-11-06)
- NPM1, FLT3, and KMT2A mutation prevalence data (filed 2025-11-06)
- MEN1 mutations and menin-resistant population discussion (filed 2025-11-06)
- Reference to 10-K for fiscal year ended December 31, 2024 filed March 19, 2025 (filed 2025-11-06)
- Reworded:
- Opening MD&A reference changed from interim condensed consolidated financial statements to unaudited condensed consolidated financial statements (filed 2026-05-12)
- Reference period changed from fiscal year ended December 31, 2024 to year ended December 31, 2025 (filed 2026-05-12)
- Company identifier in parentheses changed from corporate entity context to 'Damora Therapeutics, Inc. and its consolidated subsidiaries taken as a whole' (filed 2026-05-12)
- Forward-looking statements examples changed to focus on expected results, outcomes, and timing rather than generic plans and objectives (filed 2026-05-12)
- Notes:
- The older filing (2025-11-06) references a company with ticker GLTO in the accession URL, while the newer filing (2026-05-12) references DMRA, suggesting a potential company name or ticker change
- The two filings appear to describe completely different companies and business models with no operational continuity, which may indicate a merger or complete business pivot
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 90 days0 buys · 1 sell ($7345) — 1 selling insider
- Last 180 days0 buys · 1 sell ($7345) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-06. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about DMRA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding DMRA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 11,762,922
- Reported value $304,659,680
reported quarterly holdings change (2025-12-31 → 2026-03-31): 2 new, 2 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
DMRA had 4,893,454 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
DMRA had 7.93% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 11.71 days to cover at the same settlement.
- Reported short interest (shares) 4,893,454
- Short interest (% of shares outstanding) 7.93%
- Prior settlement (shares) 4,688,241
- Reported change 4.38%
- Days to cover (reported) 11.71
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare DMRA vs…
DAMORA THERAPEUTICS INC is found in…
DMRA ranks in…
Frequently asked questions
What does DAMORA THERAPEUTICS INC (DMRA) do?
Damora Therapeutics is a biopharmaceutical company developing therapies for hematologic disorders, specifically targeting myeloproliferative neoplasms (MPNs). The company was created through an acquisition of Pre-Acquisition Damora in November 2025 and obtained a portfolio of three preclinical antibody product candidates (DMR-001, DMR-002, and DMR-003) designed to target mutant calreticulin (mutCALR) through a licensing option agreement with Paragon Therapeutics.
What sector is DAMORA THERAPEUTICS INC (DMRA) in?
DAMORA THERAPEUTICS INC (DMRA) is classified in the Health Care sector. Its industry is Monoclonal antibodies and immuno-oncology. It trades on NASDAQ.
Who are DAMORA THERAPEUTICS INC's (DMRA) competitors?
Notable peers of DAMORA THERAPEUTICS INC (DMRA) include Incyte, Bristol Myers Squibb, Geron Corporation, AbbVie and Novartis. This peer set is informational only — not financial advice.
Is DAMORA THERAPEUTICS INC (DMRA) overbought or oversold right now?
DAMORA THERAPEUTICS INC (DMRA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 54, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on DMRA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.